Arcellx, Inc. (ACLX)
NASDAQ: ACLX · Real-Time Price · USD
76.87
+1.66 (2.21%)
Sep 16, 2025, 1:52 PM EDT - Market open
Arcellx Revenue
Arcellx had revenue of $7.55M in the quarter ending June 30, 2025, a decrease of -72.41%. This brings the company's revenue in the last twelve months to $56.98M, down -60.64% year-over-year. In the year 2024, Arcellx had annual revenue of $107.94M, down -2.16%.
Revenue (ttm)
$56.98M
Revenue Growth
-60.64%
P/S Ratio
72.41
Revenue / Employee
$349,564
Employees
163
Market Cap
4.26B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 107.94M | -2.38M | -2.16% |
Dec 31, 2023 | 110.32M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ACLX News
- 5 days ago - Arcellx, Inc. (ACLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 12 days ago - Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference - Business Wire
- 5 weeks ago - Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025 - Seeking Alpha
- 5 weeks ago - Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights - Business Wire
- 2 months ago - Arcellx: Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market - Seeking Alpha
- 4 months ago - Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 - Business Wire
- 4 months ago - Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma - Business Wire
- 4 months ago - Arcellx Provides First Quarter 2025 Financial Results and Business Highlights - Business Wire